In silico screening of some OLD drugs for NEW approaches in heart failure
Abstract
Ligand GSK-3β ΔG (kcal/mol) Ligand GSK-3β ΔG (kcal/mol) Gliquidone -11.78 Sitagliptin -7.73 Glimepiride -10.25 Riboflavin -7.59 Glibenclamide -9.72 Resveratrol -7.43 Atorvastatin -9.67 Coenzyme Q10 -7.38 Simvastatin -9.48 I3M -7.34 Rutin -9.41 Diclofenac -7.22 Glipizide -9.41 Pantoprazole -7.08 Fluvastatin -9.12 Cetirizine -6.98 Lovastatin -9.08 Dipyridamole -6.85 Ezetimibe -8.99 Biotin -6.85 Linagliptin -8.94 Naproxen -6.79 Curcumin -8.92 Famotidine -6.78 Vitamin E -8.89 Ibuprofen -6.78 Demethoxycurcumin -8.88 Naphazoline -6.63 Indomethacin -8.68 Xylometazoline -6.6
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.